Homeopathy 2016; 105(02): 194-201
DOI: 10.1016/j.homp.2015.09.008
Original Paper
Copyright © The Faculty of Homeopathy 2015

A comparative consecutive case series of 20 children with a diagnosis of ADHD receiving homeopathic treatment, compared with 10 children receiving usual care

Philippa Fibert
1   Goldsmiths, University of London, New Cross, London SE14 6NW, UK
2   School of Health and Related Research, University of Sheffield, 30 Regent Court, Sheffield S1 4DA, UK
Clare Relton
2   School of Health and Related Research, University of Sheffield, 30 Regent Court, Sheffield S1 4DA, UK
Morag Heirs
3   Northern College of Acupuncture, 61 Micklegate, York YO1 6LJ, UK
Deborah Bowden
1   Goldsmiths, University of London, New Cross, London SE14 6NW, UK
› Author Affiliations
Further Information

Publication History

Received24 March 2015
revised13 August 2015

accepted25 September 2015

Publication Date:
28 December 2017 (online)

20 consecutively enrolled children age 5–16 with Attention Deficit Hyperactivity Disorder (ADHD) received treatment by a homeopath (8 consultations and individualized remedies) for one year. Ten subsequently enrolled children received similar time and attention for 4 months. The study explored optimum treatment protocols; the effectiveness, deliverability and acceptability of treatment; and the feasibility of outcome measurement and recruitment.

Parents completed Conners' Parent Rating Scale, Revised Long Version (CPRS-R:L) every 4 months, from which DSMIV total scores were extracted; and Measure Your Own Medical Outcome Profile (MYMOP) every consultation.

An interaction between time (baseline/4 months) and group (treatment/non-treatment) was found .756 F (1,28) = 9.06, p = 0.005. The intervention was associated with statistically significant improvements in treated children over the year: CPRS-R:L (t (18) = 4.529, p ≤ 0.000); MYMOP (t (18) = 6.938, p ≤ 0.000). Mean DSMIV total t scores decreased at each time point: baseline: 85 (SD 5.1); 4 months 76.2 (SD 10.9); and 12 months 71.5 (SD 12.77).

Recruitment of control participants was problematic. Recruitment to treatment was feasible via ADHD support groups, charities, police support agencies and social services, not schools or NHS services. Attending appointments was problematic for some participants, but home visits did not improve uptake. The best venue was a familiar clinic. Some participants took medicines inappropriately, but generally taking homeopathic remedies was acceptable and well implemented. CPRS-R:L (80 items) was problematic for some parents. MYMOP was preferred by parents but not acceptable to stakeholders. In this small consecutive sample the intervention was associated with improvements in criminality, anger and children with a concomitant diagnosis of Autism Spectrum Disorder ASD.

Treatment by a homeopath was associated with sustained, increasing improvements and the intervention was acceptable to participants. More methodically rigorous research is warranted. “We recommend that future research in this area uses comparative effectiveness randomised controlled trial designs. We also recommend that these trials measure outcomes of relevance to stakeholder needs – the people and services who care for those with ADHD – parents, teachers and social workers and the criminal justice system”.

  • References

  • 1 Young S., Wells J., Gudjonsson G. Predictors of offending among prisoners: the role of Attention Deficit Hyperactivity Disorder (ADHD) and substance use. J Psychopharmacol 25 (11) 2011; 1524-1532.
  • 2 Brazier J., Peasgood T., Biggs K. Assessing the impact of children with ADHD on the health and wellbeing of their families (Shire Pharmaceuticals funded project 2009–11). 2014. Unpublished personal communications.
  • 3 Wigal S.B., Wong A.A., Jun A., Stehli A., Steinberg-Epstein R., Lerner M.A. Adverse events in medication treatment-naive children with attention-deficit/hyperactivity disorder: results from a small, controlled trial of lisdexamfetamine dimesylate. J Child Adolesc Psychopharmacol 2012; 22 (02) 149-156.
  • 4 Stein M.A., Weiss M., Hlavaty L. ADHD treatments, sleep, and sleep problems: complex associations. Neurotherapeutics 2012; 9 (03) 509-551.
  • 5 Gajria K., Lu M., Sikirica V. et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder – a systematic literature review. Neuropsychiatr Dis Treat 2014; 10: 1543-1569.
  • 6 van de Loo-Neus Gigi HH., Rommelse Nanda., Buitelaar Jan K. To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended?. Eur Neuropsychopharm 2011; 21 (08) 584-599.
  • 7 Sinha D., Efron D. Complementary and alternative medicine use in children with attention deficit hyperactivity disorder. J Paediatr Child Health 2005; 41 (12) 23-26.
  • 8 Bussing R., Zima B.T., Gary F.A., Garvan C.W. Use of complementary and alternative medicine for symptoms of attention-deficit hyperactivity disorder. Psychiat Serv 2002; 53 (09) 1096-1102.
  • 9 Foisy M., Williams K. Non pharmacological treatments for attention deficit hyperactivity disorder in children and adolescents: an overview of reviews. Evid-based Child Health 2011; 6: 283-297.
  • 10 Strauss L.C. The efficacy of a homeopathic preparation in the management of ADHD. Biochem Ther 2000; XVII: 02.
  • 11 Razlog R., Pellow J., White SJ. A pilot study on the efficacy of Valeriana officinalis mother tincture and Valeriana officinalis 3X in the treatment of attention deficit. Health SA Gesondheid, Accessed at: http://www.hsag.co.za/index.php/HSAG/article/view/603/779. Date accessed: 14 May. 2013.
  • 12 Lamont J. Homeopathic treatment of attention deficit disorder. Br Hom J 1997; 86: p196-200.
  • 13 Frei H., Everts R., vonAmmon K. et al Homeopathic treatment of children with attention-deficit hyperactivity disorder: a randomised, double blind, placebo controlled crossover trial. Eur J Paediatr 2005; 164: 758-767.
  • 14 Jacobs J., Williams A.-L., Girard C., Njike V. Yanchou., Katz D. Homeopathy for attention-deficit/hyperactivity disorder: a pilot randomised-controlled trial. J Altern Complement Med 2005; (05) 799-806 Oct 11.
  • 15 Oberai S.P., Varanasi G.R., Mishra A., Singh V., Nayak C. Homoeopathic management of attention deficit hyperactivity disorder: a randomised placebo-controlled pilot trial. Indian J Res Homoeopathy 2013; 7: 4.
  • 16 Frei H., Thurneysen A. Treatment for hyperactive children:homeopathy and methylphenidate compared in a family setting. Br Hom J 2001; 90: 183-188.
  • 17 Brulé D., Sulea L., Landau-Halpern B. et al An open-label pilot study of homeopathic treatment of attention deficit hyperactivity disorder in children and youth. Forsch Komplementmed 2014; 21 (05) 302-309.
  • 18 Barvalia P., Piyush M. Oza., Daftary A.H., Patil V.S., Agarwal V.S., Ashish R.M. Effectiveness of homoeopathic therapeutics in the management of childhood autism disorder. Indian J Res Homoeopathy 2014; 8 (03) 147-159.
  • 19 Coulter M.K., Dean M.E. Homeopathy for attention deficit/hyperactivity disorder or hyperkinetic disorder. (Systematic Review). Cochrane Database Syst Rev 2007; 04.
  • 20 Goldacre B. Meta-analyses of homeopathy trials – the author's reply. Lancet 371 2008; 985.
  • 21 Craig P., Dieppe P., Macintyre S. et al. Interventions: new guidance. 2008. MRC; London.:
  • 22 Di Blasi Z., Harkness E., Ernst E., Georgiou A., Kleijnen J. Influence of context effects on health outcomes: a systematic review. Lancet 2001; 357 9258 757-762.
  • 23 Ernst E. Placebo, deceit and complementary/alternative medicine. Climacteric 2007; 10 (02) 85-87.
  • 24 Brien S., Lachance L., Prescott P., McDermott C., Lewith G. Homeopathy has clinical benefits in rheumatoid arthritis patients that are attributable to the consultation process but not the homeopathic remedy: a randomized controlled clinical trial. Rheumatology 2011; 50 (06) 1070-1082.
  • 25 Conners C.K., Campbell M., Fitzpatrick R. et al. Conners rating scales (revised), technical manual. 2005. MHS; Toronto.:
  • 26 Paterson C. Measuring outcomes in primary care: a patient generated measure, MYMOP, compared with the SF-36 health survey. BMJ 1996; 312: 1016-1020.
  • 27 Paterson C., Britten N. In pursuit of patient-centred outcomes: a qualitative evaluation of MYMOP, Measure Yourself Medical Outcome Profile. J Health Serv Res Policy 2000; 5: 27-36.
  • 28 Smits T. Autism beyond despair. CEASE therapy. 2010. Emyriss Publishers.;
  • 29 Fibert P. Case report of a 16 year old youth with diagnoses of Attention Deficit Hyperactivity Disorder (ADHD), Asperger's syndrome and dyslexia receiving homeopathic and tautopathic treatment. EuJIM 2015; 7 (03) 312-317.
  • 30 Glass G.V., Peckham P.D., Sanders J.R. Consequences of failure to meet assumptions underlying analysis of variance and covariance. Educ Res 1972; 42: 237-288.
  • 31 Von Ammon K., Sauter U., Frei H., Kretschmar S., Thurneysen A., Frei-Erb M. Classical homeopathy helps hyperactive children–a 10-year follow-up of homeopathic and integrated medical treatment in children suffering from attention deficit disorder with and without hyperactivity. EuJIM 2012; 4 (01) 73-74.
  • 32 Jensen P.S., Youngstrom E.A., Steiner H. et al. Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: implications for medication studies. J Amer Acad Child Adolesc Psy 2007; 46 (03) 309-322.
  • 33 Satterfield J.H., Faller K.J., Crinella Francis M. et al. A 30-year prospective follow-up study of hyperactive boys with conduct problems: adult criminality. J Amer Acad Child Psy 2007; 46 (05) 601-610.
  • 34 Van der Oord S., Prins P.J.M., Oosterlaan J. et al. The adolescent outcome of children with attention deficit hyperactivity disorder treated with methylphenidate or methylphenidate combined with multimodal behaviour therapy: results of a naturalistic follow-up study. Clin Psychol Psychot 2012; 19 (03) 270-278.